# Advanced Enzyme Technologies (NSE: ADVENZYMES) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ADVENZYMES · Pivot · prices to 21 Oct 2026

Advanced Enzyme Technologies (NSE: ADVENZYMES) closed at ₹263.05 on 21 Oct 2026. With a market capitalisation of ₹4,184 Cr, it ranks 814th by market cap among the 3,928 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Specialty Chemicals.

Its return on equity was 9.2% in FY25. Its 52-week range is ₹251.95 (30 Mar 2026) to ₹419.00 (11 May 2026); the last close is 37.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹203 Cr (+21.6% year on year) and net profit ₹45 Cr (+69.3%), on a consolidated basis. Promoters held 43.24% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹263.05 |
| Market cap | ₹4,184 Cr |
| ROE | 9.2% (FY25) |
| ROCE | 12.5% (FY25) |
| Debt to equity | 0.02 |
| 52-week high | ₹419.00 (11 May 2026) |
| 52-week low | ₹251.95 (30 Mar 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹203 Cr | +21.6% | ₹45 Cr | +69.3% | ₹3.84 |
| Q3 FY26 | ₹172 Cr | +1.7% | ₹43 Cr | +11.1% | ₹3.80 |
| Q2 FY26 | ₹185 Cr | +26.3% | ₹45 Cr | +34.0% | ₹3.87 |
| Q1 FY26 | ₹186 Cr | +20.3% | ₹40 Cr | +15.6% | ₹3.57 |
| Q4 FY25 | ₹167 Cr | +5.9% | ₹27 Cr | −10.5% | ₹2.37 |
| Q3 FY25 | ₹169 Cr | +5.1% | ₹39 Cr | −8.5% | ₹3.36 |
| Q2 FY25 | ₹146 Cr | −7.4% | ₹33 Cr | −5.1% | ₹2.94 |
| Q1 FY25 | ₹155 Cr | +4.9% | ₹35 Cr | +19.1% | ₹3.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹637 Cr | ₹134 Cr |
| FY24 | ₹624 Cr | ₹137 Cr |
| FY23 | ₹541 Cr | ₹104 Cr |
| FY22 | ₹529 Cr | ₹124 Cr |
| FY21 | ₹502 Cr | ₹151 Cr |
| FY20 | ₹444 Cr | ₹133 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 43.24%
- Foreign institutions: 26.71%
- Domestic institutions: 4.78%
- Non-institutions: 25.27%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Entero Healthcare Solutions](https://app.pivotnow.in/stock/ENTERO) | — | ₹4,741 Cr | — | — |
| [Gujarat Themis Biosyn](https://app.pivotnow.in/stock/GUJTHEM) | — | ₹4,186 Cr | — | — |
| [Zota Health Care](https://app.pivotnow.in/stock/ZOTA) | — | ₹3,966 Cr | — | — |
| [IOL Chemicals and Pharmaceuticals](https://app.pivotnow.in/stock/IOLCP) | — | ₹3,822 Cr | — | — |
| [RPG Life Sciences](https://app.pivotnow.in/stock/RPGLIFE) | — | ₹3,766 Cr | — | — |
| [Gufic Biosciences](https://app.pivotnow.in/stock/GUFICBIO) | — | ₹3,562 Cr | — | — |

## Questions and answers

### What is the share price of Advanced Enzyme Technologies today?

Advanced Enzyme Technologies (NSE: ADVENZYMES) last closed at ₹263.05 on 21 Oct 2026. Its 52-week high is ₹419.00 and its 52-week low is ₹251.95.

### What is the market cap of Advanced Enzyme Technologies?

Advanced Enzyme Technologies' market capitalisation is ₹4,184 Cr (₹4,184 Cr) at the — close, ranking 814th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Advanced Enzyme Technologies?

Return on equity was 9.2% in FY25 and return on capital employed was 12.5% in FY25 (consolidated figures).

### Is Advanced Enzyme Technologies a debt-free company?

Advanced Enzyme Technologies is close to debt-free: its debt-to-equity ratio was 0.02 in FY25.

### What were Advanced Enzyme Technologies' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Advanced Enzyme Technologies reported revenue of ₹203 Cr, +21.6% year on year, and net profit of ₹45 Cr, +69.3% year on year.

### What is the shareholding pattern of Advanced Enzyme Technologies?

As of 30 Jun 2026: promoters 43.24%, foreign institutions 26.71%, domestic institutions 4.78%, non-institutions 25.27%.

### Who are Advanced Enzyme Technologies' competitors?

The listed Pharma & Healthcare companies closest to Advanced Enzyme Technologies by market cap are Entero Healthcare Solutions, Gujarat Themis Biosyn, Zota Health Care, IOL Chemicals and Pharmaceuticals, RPG Life Sciences and Gufic Biosciences.

### Is Advanced Enzyme Technologies a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Advanced Enzyme Technologies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ADVENZYMES against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.